All In Biotech

Drug Trial Radar · NCT04478734

Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease

Multicentric Trial on the Use of Combined Therapy of Thiamine and Biotine in Patients With Huntington´s Disease

Last checked: Nov 20, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Apr 12, 2023

Primary completion

Jun 30, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Consorcio Centro de Investigación Biomédica en Red (CIBER)
First posted
Jul 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and tolerability of combined oral thiamine with biotin therapy in patients with Huntington´s disease in mild to moderate stages and it is intended to evaluate the biological effect of the treatment in the central nervous system of these patients using as the main biomarker the increase in the level of thiamine monophosphate (TMP) in cerebrospinal fluid (CSF) of these patients with Huntington Disease (HD) during a follow-up period of one year. Our main hypothesis is that combined thiamine-biotin oral therapy is a secure and well-tolerated treatment, potentially capable of modifying the disease course or avoiding the progression of symptoms in early-stages HD patients

Conditions

  • Huntington Disease

Interventions

  • Moderate doses of Thiamine y BiotinDrug

    Thiamine 600 mg every day + Biotin 150mg every day

  • High doses of Thiamine y BiotinDrug

    Thiamine 1200 mg every day + Biotin 300mg every day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events as assessed by clinical examination anamnesis and Analytical monitoring with hematological and biochemical control (hepatic and renal function)Time frame: From signature of informed consent form, at all scheduled visits, to end of follow up week 52

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Ramón y Cajal

    Madrid, Spain · Recruiting

  • Hospital Universitario de San Sebastián

    San Sebastián, San Sebastian, Spain · Recruiting

  • Virgen del Rocío Hospital

    Seville, Seville, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.